BeiGene vs ONCOMATRYX
BeiGene vs ONCOMATRYX, compared side by side on 18 data points: what each one does, how big it is, what it has raised, the tech running each site, and what users report. We score both out of 100 on traction, team and visibility: BeiGene is on 64/100 and ONCOMATRYX on 50/100.
Where each one leads
BeiGene
- our overall score: 64/100 against 50/100
- agent readiness: 50/100 against 36/100
- domain rating: 68/100 against 26/100
- funding raised: $358M against $107M
ONCOMATRYX
Leads on none of the measures we hold for both companies.
At a glance
| Measure | BeiGene | ONCOMATRYX |
|---|---|---|
| What it is | A global oncology company developing and commercializing innovative cancer treatments. | Developing Quantum ADCs against the tumor microenvironment for innovative cancer therapies. |
| Category | Biotech, MedTech, HealthTech, Genomics | Biotechnology, Pharmaceuticals, Healthcare, Biotech |
| Sells toBusiness model | B2B | B2B |
| Offering | Platform | Services |
| Founded | 2010 | 2009 |
| Headquarters | Cambridge, United States | Derio, Spain |
| Status | Active | Active |
Size, funding and growth
| Measure | BeiGene | ONCOMATRYX |
|---|---|---|
| Employees | Not published | 36 |
| Open roles | 100 | Not published |
| Total funding | $358M | $107M |
| Latest round | Secondary Offering | Funding Round |
| Valuation | $15B | Not published |
| LinkedIn followers | Not published | 5,170 |
StartupHub scores
Our own 0-100 ratings. They measure company strength and site quality, not which product suits you.
| Measure | BeiGene | ONCOMATRYX |
|---|---|---|
| StartupHub scoreOur 0-100 rating | 64/100 | 50/100 |
| Traction | 40/100 | 56/100 |
| Team | 30/100 | 30/100 |
| Search visibility | 17/100 | 37/100 |
| Quality | 88/100 | 55/100 |
| Agent readinessHow well an AI agent can read and act on the site | D (50/100) | F (36/100) |
| Domain ratingLink authority, 0-100 | 68/100 | 26/100 |
Technology
Detected on each public site, so it reflects the marketing stack as well as the product.
| Measure | BeiGene | ONCOMATRYX |
|---|---|---|
| Hosting | Not detected | Self Managed |
| CDN | Cloudflare | Not detected |
| CMS | WordPress | WordPress |
| Frameworks | Jquery, Tailwind CSS, Bootstrap | Jquery |
| Analytics | Not detected | Google Analytics 4 |
BeiGene vs ONCOMATRYX: common questions
Which is better, BeiGene or ONCOMATRYX?
On our 0-100 score BeiGene rates higher (64/100 against 50/100). The score weights traction, team, visibility and profile completeness, so it reflects company strength rather than which product suits you. We compare the two on 18 data points above: read the rows that match what you are buying for.
How do BeiGene and ONCOMATRYX compare on the numbers?
BeiGene leads on our overall score (64/100 against 50/100), agent readiness (50/100 against 36/100), domain rating (68/100 against 26/100), funding raised ($358M against $107M).
Read the full BeiGene review and pricing or the ONCOMATRYX review and pricing. You can also browse other BeiGene alternatives we track.